Table 2.
Patient demographic and characteristics at time of switch among stable patients on HIV treatment at the Themba Lethu Clinic in Johannesburg South Africa after propensity score matching (n = 1588).
| DTG unexposed (n = 794) |
DTG exposed (n = 794) |
Total (n = 1588) |
|
|---|---|---|---|
| Sex (%) | |||
| Female | 387 (48.7) | 384 (48.4) | 771 (48.6) |
| Male | 407 (51.3) | 410 (51.6) | 817 (51.5) |
| Age (years) at ART initiation (%) | |||
| 16–24.9 | 113 (14.2) | 103 (13.0) | 216 (13.6) |
| 25–29.9 | 52 (6.55) | 55 (6.93) | 107 (6.74) |
| 30–39.9 | 277 (34.9) | 265 (33.4) | 542 (34.1) |
| 40–49.9 | 237 (29.8) | 256 (32.2) | 493 (31.1) |
| ≥50 | 115 (14.5) | 115 (14.5) | 230 (14.5) |
| Age (median (IQR)) | 28.6 (31.8, 45.7) | 39.0 (31.7, 45.8) | 38.8 (31.7, 45.8) |
| CD4 count (cells/mm3) at time of switch (%) | |||
| <200 | 51 (6.42) | 63 (7.93) | 114 (7.18) |
| 200–299 | 115 (14.5) | 121 (15.2) | 236 (14.9) |
| 300–399 | 136 (17.1) | 136 (17.1) | 272 (17.1) |
| 400–499 | 128 (16.1) | 122 (15.4) | 250 (15.7) |
| ≥500 | 364 (45.8) | 352 (44.3) | 716 (45.1) |
| CD4 count (median (IQR)) | 473 (329, 621) | 470 (314, 642) | 470 (319, 631) |
| Time on ART (months) at time of switch (%) | |||
| 0–11.9 | 90 (11.3) | 89 (11.2) | 179 (11.3) |
| 12–23.9 | 165 (20.8) | 147 (18.5) | 312 (19.7) |
| 24–35.9 | 100 (12.6) | 99 (12.5) | 199 (12.5) |
| 36–47.9 | 71 (8.94) | 77 (9.70) | 148 (9.32) |
| 48–59.9 | 67 (8.44) | 71 (8.94) | 138 (8.69) |
| ≥60 | 301 (37.9) | 311 (39.2) | 612 (38.5) |
| Time on ART (median (IQR)) | 42.2 (19.9, 70.6) | 45.4 (20.2, 86.5) | 43.4 (20.1, 74.8) |
| Body Mass Index at time of switch (kg/m2) (%) | |||
| <18.5 | 21 (2.64) | 25 (3.15) | 46 (2.90) |
| 18.5–24.9 | 281 (35.4) | 285 (35.9) | 566 (35.6) |
| 25–29.9 | 214 (27.0) | 225 (28.3) | 439 (27.6) |
| ≥30.0 | 278 (35.0) | 259 (32.6) | 567 (33.8) |
| Body Mass Index (median (IQR)) | 26.6 (23.0, 31.3) | 27.0 (22.8, 31.5) | 27.0 (22.9, 31.4) |
| Haemoglobin (ug/dL) at time of switch (%) | |||
| <10.0 | 10 (1.26) | 15 (1.89) | 25 (1.57) |
| ≥10.0 | 784 (98.7) | 779 (98.1) | 1563 (98.4) |
| Haemoglobin (median (IQR)) | 14.0 (12.9, 15.4) | 14.0 (12.7, 15.1) | 14.0 (12.8, 15.2) |
| Nucleoside reverse transcriptase inhibitor (%) | |||
| lamivudine | 572 (72.0) | 581 (73.2) | 1153 (72.6) |
| emtricitabine | 333 (28.0) | 213 (26.8) | 435 (27.4) |
| Unsuppressed viral load (%) | 8 (1.01) | 6 (0.76) | 14 (0.90) |
| Systolic (mm/Hg) (median (IQR)) | 128 (119, 139) | 133 (122, 141) | 130 (120, 140) |
| Diastolic (mm/Hg) (median (IQR)) | 80 (72, 87) | 83 (75, 90) | 81 (74, 89) |
| Hypertension at time of switch (%) | 128 (16.1) | 132 (16.6) | 260 (16.4) |
| 12-month outcomes | |||
| Unsuppressed viral load (%) | 8 (1.01) | 4 (0.50) | 12 (0.76) |
| Hypertension (%) | 87 (11.0) | 201 (25.3) | 288 (18.1) |
| Baseline weight (kg) (mean (SD)) | 74.0 (15.8) | 73.1 (16.9) | 73.5 (16.4) |
| Follow-up weight (kg) (mean (SD)) | 75.4 (16.3) | 75.9 (17.0) | 75.7 (16.6) |
| Mean change in weight (kg) | 1.5 (1.3) | 2.8 (6.7) | 2.12 (6.0) |
| Percent change in weight (%) | 2.2 (7.6) | 4.5 (12.2) | 3.3 (10.2) |